MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Clinical trials for MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough leukemias: experimental drug APL-4098 enters human testing
Disease control Recruiting nowThis early-stage study tests an experimental drug called APL-4098, alone or with standard chemotherapy drugs, in about 100 adults with acute myeloid leukemia (AML) or related blood cancers that have come back or not responded to treatment. The main goals are to check safety, find…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE1 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated May 17, 2026 03:11 UTC
-
New hope for High-Risk blood cancer: targeted therapy shows promise
Disease control Recruiting nowThis study tests a combination of two drugs, enasidenib and azacitidine, in people with a rare, high-risk blood cancer called IDH2-mutant myelodysplastic syndrome. The goal is to see if the treatment can control the disease and reduce side effects. About 63 participants will take…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Radioactive antibody targets leukemia before transplant
Disease control Recruiting nowThis study tests a radioactive antibody (211At-BC8-B10) given before a donor stem cell transplant for people with high-risk acute leukemias or myelodysplastic syndrome. The antibody seeks out and delivers radiation to cancer cells while sparing healthy cells. The goal is to find …
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New drug combo targets hard-to-treat leukemia in early trial
Disease control Recruiting nowThis study tests a mix of chemotherapy drugs for people newly diagnosed with a specific type of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome. The goal is to see how well the treatment kills cancer cells and what side effects it causes. About 270 adults will …
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 05, 2026 11:52 UTC
-
Radioactive antibody blasts cancer before stem cell rescue in High-Risk leukemia trial
Disease control Recruiting nowThis study tests a radioactive antibody (211At-BC8-B10) followed by a donor stem cell transplant for people with high-risk leukemia or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The antibody targets cancer cells and delivers radiation, then c…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
Immune boosting cells show promise in fighting blood cancers after transplant
Disease control Recruiting nowThis study tests whether giving patients personalized natural killer (NK) cells after chemotherapy and a cord blood transplant can help kill remaining cancer cells and reduce complications. It includes 100 adults with various blood cancers like leukemia, lymphoma, or multiple mye…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC